1
|
Rahman MM, David M, Steinberg J, Cust A, Yu XQ, Rutherford C, Banks E, Byles J, Canfell K. Association of optimism and social support with health-related quality of life among Australian women cancer survivors - A cohort study. Asia Pac J Clin Oncol 2024. [PMID: 38771455 DOI: 10.1111/ajco.14079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Revised: 04/26/2024] [Accepted: 05/06/2024] [Indexed: 05/22/2024]
Abstract
AIM Large-scale studies investigating health-related quality of life (HRQL) in cancer survivors are limited. This study aims to investigate HRQL and its relation to optimism and social support among Australian women following a cancer diagnosis. METHODS Data were from the Australian Longitudinal Study on Women's Health, a large cohort study (n = 14,715; born 1946-51), with 1428 incident cancer cases ascertained 1996-2017 via linkage to the Australian Cancer Database. HRQL was measured using the Short Form-36 (median 1.7 years post-cancer-diagnosis). Multivariable linear regression was performed on each HRQL domain, separately for all cancers combined, major cancer sites, and cancer-free peers. RESULTS Higher optimism and social support were significantly associated with better HRQL across various domains in women with and without a cancer diagnosis (p < 0.05). Mean HRQL scores across all domains for all cancer sites were significantly higher among optimistic versus not optimistic women with cancer (p < 0.05). Adjusting for sociodemographic and other health conditions, lower optimism was associated with reduced scores across all domains, with greater reductions in mental health (adjusted mean difference (AMD) = -11.54, p < 0.01) followed by general health (AMD = -11.08, p < 0.01). Social support was less consistently related to HRQL scores, and following adjustment was only significantly associated with social functioning (AMD = -7.22, p < 0.01) and mental health (AMD = -6.34, p < 0.01). CONCLUSIONS Our findings highlight a strong connection between optimism, social support, and HRQL among cancer survivors. Providing psychosocial support and addressing behavioral and socioeconomic factors and other health conditions associated with optimism and social support may improve HRQL.
Collapse
Affiliation(s)
- Md Mijanur Rahman
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
| | - Michael David
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
- School of Medicine and Dentistry, Griffith University, Queensland, Australia
| | - Julia Steinberg
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
| | - Anne Cust
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
| | - Xue Qin Yu
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
| | - Claudia Rutherford
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
- Cancer Care Research Unit (CCRU), Susan Wakil School of Nursing and Midwifery, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Emily Banks
- National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia
| | - Julie Byles
- Centre for Women's Health Research, The University of Newcastle, Newcastle, Australia
| | - Karen Canfell
- The Daffodil Centre, the University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, Australia
| |
Collapse
|
2
|
Watts C, Spillane A, Henderson MA, Cust A, Braithwaite J, Gyorki DE, Hong AM, Kelly JW, Long GV, Mar VJ, Menzies AM, Morton RL, Rapport F, Saw RPM, Schmid H, Scolyer RA, Smith AL, Winder A, Mann GJ. Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Med J Aust 2022. [DOI: 10.5694/mja2.51424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Caroline Watts
- Daffodil Centre University of Sydney and Cancer Council NSW Sydney NSW
- The Kirby Institute UNSW Sydney NSW
| | - Andrew Spillane
- Melanoma Institute Australia University of Sydney Sydney NSW
- Sydney Medical School University of Sydney Sydney NSW
- Royal North Shore Hospital Sydney NSW
- Mater Hospital Sydney NSW
| | - Michael A Henderson
- Peter MacCallum Cancer Centre Melbourne VIC
- The University of Melbourne Melbourne VIC
| | - Anne Cust
- Daffodil Centre University of Sydney and Cancer Council NSW Sydney NSW
- Melanoma Institute Australia University of Sydney Sydney NSW
| | - J Braithwaite
- Australian Institute of Health Innovation Macquarie University Sydney NSW
| | - DE Gyorki
- Peter MacCallum Cancer Centre Melbourne VIC
| | - AM Hong
- Melanoma Institute Australia University of Sydney Sydney NSW
| | - JW Kelly
- Victorian Melanoma Service Alfred Hospital Melbourne VIC
| | - GV Long
- Melanoma Institute Australia University of Sydney Sydney NSW
- Sydney Medical School University of Sydney Sydney NSW
- Royal North Shore Hospital Sydney NSW
- Mater Hospital Sydney NSW
| | - VJ Mar
- Victorian Melanoma Service Alfred Hospital Melbourne VIC
| | - AM Menzies
- Melanoma Institute Australia University of Sydney Sydney NSW
- Sydney Medical School University of Sydney Sydney NSW
- Royal North Shore Hospital Sydney NSW
- Mater Hospital Sydney NSW
| | - RL Morton
- Melanoma Institute Australia University of Sydney Sydney NSW
- NHMRC Clinical Trials Centre University of Sydney Sydney NSW
| | - F Rapport
- Australian Institute of Health Innovation Macquarie University Sydney NSW
| | - RPM Saw
- Melanoma Institute Australia University of Sydney Sydney NSW
- Sydney Medical School University of Sydney Sydney NSW
- Mater Hospital Sydney NSW
| | - H Schmid
- Daffodil Centre University of Sydney and Cancer Council NSW Sydney NSW
| | - RA Scolyer
- Melanoma Institute Australia University of Sydney Sydney NSW
- Sydney Medical School University of Sydney Sydney NSW
- Royal Prince Alfred Hospital and New South Wales Health Pathology Sydney NSW
| | - AL Smith
- Daffodil Centre University of Sydney and Cancer Council NSW Sydney NSW
| | - A Winder
- Melanoma Institute Australia University of Sydney Sydney NSW
| | - GJ Mann
- Melanoma Institute Australia University of Sydney Sydney NSW
- The John Curtin School of Medical Research Australian National University Canberra ACT
| | | |
Collapse
|
3
|
Steinberg J, Lee JY, Wang H, Law M, Smit A, Nguyen-Dumont T, Giles G, Southey M, Milne R, Mann G, MacInnis R, Cust A. 1036Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts. Int J Epidemiol 2021. [DOI: 10.1093/ije/dyab168.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
To improve melanoma early detection, tools to predict personal risk based on genetic information (polygenic risk scores, PRS) have been developed, but require external validation.
Methods
We analysed invasive melanoma incidence in UK Biobank (UKB; n = 395,647; 1,651 cases) and the Melbourne Collaborative Cohort Study (MCCS, Australia; n = 4,765; 303 cases). Three PRS were evaluated: 68 genetic variants (SNPs) at 54 loci from a 2020 meta-analysis (PRS68); 50 SNPs significant in the 2020 meta-analysis excluding UKB (PRS50); 45 SNPs at 21 loci known pre-2020 (PRS45). 10-year melanoma risks were calculated from population-level cancer registry data by age group and sex, with and without PRS adjustment.
Results
All PRS were strongly associated with melanoma incidence, including after adjustment for age, sex, ethnicity, and ease of tanning. Predicted absolute melanoma risks based on age and sex alone underestimated melanoma incidence in UKB (ratio expected/observed cases E/O=0.65, 95% confidence interval 0.62-0.68) and MCCS (E/O=0.65, 0.57-0.73). For UKB, this was reduced by PRS-adjustment, e.g. PRS50-adjusted risks E/O=0.91 (0.87-0.95). Discriminative ability for PRS68- and PRS50-adjusted absolute risks was higher than for risks based on age and sex alone (deltaAUC 0.07-0.1, p < 0.0001), and higher than for PRS45-adjusted risks (deltaAUC 0.02-0.04, p < 0.001).
Conclusions
A PRS derived from a larger, more diverse meta-analysis improves melanoma risk prediction compared to an earlier PRS. Re-calibration of absolute risks may be necessary for application to specific populations.
Key messages
A genetic score can improve prediction of melanoma risk and might help tailor melanoma prevention and early detection strategies to different risk levels.
Collapse
Affiliation(s)
- Julia Steinberg
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
| | - Jin Yee Lee
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
| | | | | | - Amelia Smit
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
| | | | | | | | - Roger Milne
- Cancer Council Victoria, Melbourne, Australia
| | - Graham Mann
- Australian National University, Canberra, Australia
| | | | - Anne Cust
- The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
| |
Collapse
|
4
|
Yardman-Frank JM, Bronner B, Rosso S, From L, Busam K, Groben P, Tucker P, Cust A, Armstrong B, Kricker A, Marrett L, Anton-Culver H, Gruber S, Gallagher R, Zanetti R, Sacchetto L, Dwyer T, Venn A, Orlow I, Kanetsky P, Luo L, Thomas N, Begg C, Berwick M. Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma. JAAD Int 2021; 4:25-27. [PMID: 34409386 PMCID: PMC8362323 DOI: 10.1016/j.jdin.2021.04.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
| | - Baillie Bronner
- University of New Mexico School of Medicine, Albuquerque, New Mexico
| | | | | | - Klaus Busam
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Pam Groben
- University of North Carolina, Chapel Hill, North Carolina
| | | | - Anne Cust
- Sydney University, New South Wales, Australia
| | | | | | | | | | | | - Rick Gallagher
- British Columbia Cancer Research Center, Vancouver, Canada
| | | | | | | | | | - Irene Orlow
- Memorial Sloan Kettering Cancer Center, New York, New York
| | | | - Li Luo
- University of New Mexico School of Medicine, Albuquerque, New Mexico
| | - Nancy Thomas
- University of North Carolina, Chapel Hill, North Carolina
| | - Colin Begg
- Memorial Sloan Kettering Cancer Center, New York, New York
| | - Marianne Berwick
- University of New Mexico School of Medicine, Albuquerque, New Mexico
| | | |
Collapse
|
5
|
Rankin N, Mcgregor D, Donnelly C, Cust A, De Abreu Lourenco R, Van Dort B, Broome K, Sharman A, Stone E. P41.07 Lung Cancer Screening: What is the State of the Evidence about Implementation? J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Weber MFW, Marshall H, Rankin N, Duffy S, Fong K, Dunlop K, Humphreys L, Smit A, Cust A, Taylor N, Mitchell G, Kang YJ, Tucker K, Jenkins M, Macrae F, Lockart I, Danta M, Armstrong B, Howe M. Cancer screening in Australia: future directions in melanoma, Lynch syndrome, and liver, lung and prostate cancers. Public Health Res Pract 2019; 29:2921910. [DOI: 10.17061/phrp2921910] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
7
|
Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, Peris K, Puig S, Menin C, De Nicolo A, Rodolfo M, Pellegrini C, Pastorino L, Evangelou E, Zhang T, Hua X, DellaValle CT, Timothy Bishop D, MacGregor S, Iles MI, Law MH, Cust A, Brown KM, Stratigos AJ, Nagore E, Chanock S, Shi J, Consortium MMA, Consortium M, Landi MT. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Hum Mol Genet 2018; 27:4145-4156. [PMID: 30060076 PMCID: PMC6240742 DOI: 10.1093/hmg/ddy282] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Revised: 06/14/2018] [Accepted: 07/24/2018] [Indexed: 02/04/2023] Open
Abstract
Melanoma heritability is among the highest for cancer and single nucleotide polymorphisms (SNPs) contribute to it. To date, only SNPs that reached statistical significance in genome-wide association studies or few candidate SNPs have been included in melanoma risk prediction models. We compared four approaches for building polygenic risk scores (PRS) using 12 874 melanoma cases and 23 203 controls from Melanoma Meta-Analysis Consortium as a training set, and newly genotyped 3102 cases and 2301 controls from the MelaNostrum consortium for validation. We estimated adjusted odds ratios (ORs) for melanoma risk using traditional melanoma risk factors and the PRS with the largest area under the receiver operator characteristics curve (AUC). We estimated absolute risks combining the PRS and other risk factors, with age- and sex-specific melanoma incidence and competing mortality rates from Italy as an example. The best PRS, including 204 SNPs (AUC = 64.4%; 95% confidence interval (CI) = 63-65.8%), developed using winner's curse estimate corrections, had a per-quintile OR = 1.35 (95% CI = 1.30-1.41), corresponding to a 3.33-fold increase comparing the 5th to the 1st PRS quintile. The AUC improvement by adding the PRS was up to 7%, depending on adjusted factors and country. The 20-year absolute risk estimates based on the PRS, nevus count and pigmentation characteristics for a 60-year-old Italian man ranged from 0.5 to 11.8% (relative risk = 26.34), indicating good separation.
Collapse
Affiliation(s)
- Fangyi Gu
- Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ting-Huei Chen
- Department of Mathematics and Statistics, Laval University, Quebec, Canada
| | - Ruth M Pfeiffer
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | | | - Donato Calista
- Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy
| | - Paola Ghiorzo
- Department of Internal Medicine and Medical Specialties, University of Genoa and Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy
| | - Ketty Peris
- Institute of Dermatology, Catholic University, Rome, Italy
| | - Susana Puig
- Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Valencia, Spain
| | - Chiara Menin
- Department of Immunology and Molecular Oncology, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy
| | - Arcangela De Nicolo
- Cancer Genomics Program, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy
| | - Monica Rodolfo
- Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | - Lorenza Pastorino
- Department of Internal Medicine and Medical Specialties, University of Genoa and Genetics of Rare Cancers, Ospedale Policlinico San Martino, Genoa, Italy
| | - Evangelos Evangelou
- Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece
- Department of Epidemiology and Biostatistics, Imperial College London, London, UK
| | - Tongwu Zhang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Xing Hua
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Curt T DellaValle
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - D Timothy Bishop
- Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - Stuart MacGregor
- Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Mark I Iles
- Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, UK
| | - Matthew H Law
- Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Anne Cust
- Sydney School of Public Health, and Melanoma Institute Australia, The University of Sydney, Sydney, Australia
| | - Kevin M Brown
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Alexander J Stratigos
- 1 Department of Dermatology–Venereology, National and Kapodistrian University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Eduardo Nagore
- Department of Dermatology, Instituto Valenciano de Oncología, València, Spain
| | - Stephen Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jianxin Shi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | | | | | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
8
|
Bishop DT, Iles MM, Newton-Bishop JA, Barrett JH, Trouwer A, Law M, MacGregor S, Duffy D, Martin NG, Hayward N, Cust A, Landi MT, Goldstein A, Shi J, Machiela M, Demenais F, Kanetsky P. Abstract 234: Understanding melanoma susceptibility through GWAS of risk phenotypes. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Melanoma susceptibility SNPs can be categorized by their impact on known susceptibility phenotypes (pigmentation, nevus count, telomere length, or other). In an ongoing meta-analysis of melanoma, at this stage involving 17,800 cases but soon expanding to more than 30,000 cases, 26 SNPs have achieved genome-wide significance. UK Biobank is a population-based cohort of 500,000 UK persons aged at recruitment 40-69 years; participants reported pigmentation characteristics including ease of tanning, natural hair color, skin color (in the absence of tan), and number of childhood sunburns. To conduct analyses, we separately analyzed the red hair phenotype while ordering the other hair colors from black to blond. Among the 26 SNPs from the melanoma GWAS, 15 were associated with at least one pigmentation factor assessed in UK Biobank (each at p <10-5) with 5 being associated with all pigmentation factors (e.g., SLC45A2, ASIP, MC1R) while others were associated with a subset of factors (e.g., RAD23B/TAL2 was strongly associated with hair color alone). 13 of the melanoma SNPs were associated with "ease of tanning." Detailed analysis of "ease of tanning" SNPs found 29 genome-wide significant in a subset of UK Biobank, of which 13 were associated with melanoma risk (p <0.001) but notably 4 of the SNPs showed no evidence of melanoma risk even when being among the strongest effects for "ease of tanning" and the remainder showing weaker evidence of association. For all pigmentation factors (except having red hair), the effect sizes for a SNP on melanoma risk and pigmentation were highly correlated. We examined the 26 melanoma SNPs in recent GWAS of nevus count and telomere length, and similarly observed overlaps with these phenotypes. While the telomere, nevus and pigmentation instruments were largely distinct, we found evidence of some overlap in genetic susceptibility (for instance, the PLA2G6 SNP rs2092180 is strongly associated with nevus count, ease of tanning and skin color [all p <10-12]). Combined analysis of the melanoma GWAS results with the GWAS of each of these phenotypes provides overwhelming evidence of further susceptibility loci, indicating that GWAS of intermediate phenotypes can benefit identification of the underlying genetic profile.
Supported by Cancer Research UK (C588/A19167) & NIH (CA083115). This research has been conducted using the UK Biobank Resource.
Citation Format: David T. Bishop, Mark M. Iles, Julia A. Newton-Bishop, Jennifer H. Barrett, Adam Trouwer, Matthew Law, Stuart MacGregor, David Duffy, Nicholas G. Martin, Nicholas Hayward, Anne Cust, Maria T. Landi, Alisa Goldstein, Jianxin Shi, Mitch Machiela, Florence Demenais, Peter Kanetsky, GenoMEL & MELANOSTRUM. Understanding melanoma susceptibility through GWAS of risk phenotypes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 234.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Anne Cust
- 3University of Sydney, Sydney, Australia
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Cormie P, Atkinson M, Bucci L, Cust A, Eakin E, Hayes S, McCarthy AL, Murnane A, Patchell S, Adams D. Clinical Oncology Society of Australia position statement on exercise in cancer care. Med J Aust 2018; 209:184-187. [DOI: 10.5694/mja18.00199] [Citation(s) in RCA: 174] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 03/27/2018] [Indexed: 12/13/2022]
Affiliation(s)
- Prue Cormie
- Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC
| | - Morgan Atkinson
- Youth Cancer Services South Australia and Northern Territory, Adelaide, SA
| | - Lucy Bucci
- Peter MacCallum Cancer Centre, Melbourne
| | - Anne Cust
- Cancer Epidemiology and Prevention Research Group, University of Sydney, Sydney, NSW
- Melanoma Institute Australia, Sydney, NSW
| | | | - Sandra Hayes
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD
| | | | | | | | - Diana Adams
- Macarthur Cancer Therapy Centre, South Western Sydney Local Health District, Sydney, NSW
| |
Collapse
|
10
|
Dieng M, Kasparian NA, Mireskandari S, Butow P, Costa D, Morton R, Mann G, Menzies S, Cust A. Psychoeducational intervention for people at high risk of developing another melanoma: a pilot randomised controlled trial. BMJ Open 2017; 7:e015195. [PMID: 29018064 PMCID: PMC5652456 DOI: 10.1136/bmjopen-2016-015195] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
INTRODUCTION Information and psychological needs have been reported as one of the greatest areas of unmet needs for patients with melanoma. To respond to these needs, we developed the Melanoma Care Intervention, a developed psychoeducational intervention for people at high risk of developing another melanoma comprising of a newly developed melanoma educational booklet and individually tailored telephone support sessions provided by trained psychologists. The purpose of this study was to investigate the acceptability and feasibility of the Melanoma Care Intervention. METHODS Twenty-four adults (14 men, 10 women, mean age: 58 years, SD: 12.2) at high risk of developing a subsequent primary melanoma were recruited and randomly assigned 1:1 to the intervention (a psychoeducational booklet, a Cancer Council booklet on melanoma and up to five telephone-based sessions with a psychologist) or usual care (Cancer Council booklet only). Acceptability, feasibility, fear of cancer recurrence and secondary psychosocial outcomes were assessed at baseline, 1 and 6 months. RESULTS Satisfaction and perceived benefits were rated highly for all intervention components, particularly the telephone-based psychology sessions (mean satisfaction and benefits: both 9.27 out of 10, SD=2.41). The quality of information and support provided throughout the trial was rated as 'high' by the intervention group, with a mean score of 4.6 out of a possible 5 (SD=0.9) and 4.2 (SD=1.2) for the control group. CONCLUSIONS The intervention was feasible and acceptable for improving psychological adjustment. Timely access to effective, evidence-based, psychological care is a recognised need for people with melanoma. The intervention is designed to directly address this need in a way that is feasible in a clinical setting, acceptable to patients and health professionals. TRIAL REGISTRATION NUMBER The trial was registered with the Australian and New Zealand Clinical Trials Registry on 19/03/2013 (Registration Number: ACTRN12613000304730).
Collapse
Affiliation(s)
- Mbathio Dieng
- Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia
| | - N A Kasparian
- Discipline of Paediatrics, School of Women's and Children's Health, UNSW Medicine, The University of New South Wales, Sydney, Australia
| | - Shab Mireskandari
- Centre for Medical Psychology & Evidence-based Decision-making, The University of Sydney, Sydney, New South Wales, Australia
| | - Phyllis Butow
- Psycho-oncology Co-operative Research Group, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia
| | - Daniel Costa
- Pain Management Research Institute, University of Sydney at Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | - Rachael Morton
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia
| | - Graham Mann
- Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia
- Melanoma Institute Australia, The University of Sydney, North Sydney, Australia
| | - Scott Menzies
- Discipline of Dermatology, Sydney Medical School, The University of Sydney, Camperdown, Australia
- The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Camperdown, Australia
| | - Anne Cust
- Cancer Epidemiology and Prevention Research, Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
- Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia
| |
Collapse
|
11
|
Abstract
The epidemiology of melanoma is complex, and individual risk depends on sun exposure, host factors, and genetic factors, and in their interactions as well. Sun exposure can be classified as intermittent, chronic, or cumulative (overall) exposure, and each appears to have a different effect on type of melanoma. Other environmental factors, such as chemical exposures-either through occupation, atmosphere, or food-may increase risk for melanoma, and this area warrants further study. Host factors that are well known to be important are the numbers and types of nevi and the skin phenotype. Genetic factors are classified as high-penetrant genes, moderate-risk genes, or low-risk genetic polymorphisms. Subtypes of tumors, such as BRAF-mutated tumors, have different risk factors as well as different therapies. Prevention of melanoma has been attempted using various strategies in specific subpopulations, but to date optimal interventions to reduce incidence have not emerged.
Collapse
Affiliation(s)
- Marianne Berwick
- Department of Internal Medicine, University of New Mexico, MSC10-5550, Albuquerque, NM, 87131-0001, USA.
| | - David B Buller
- Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO, 80401, USA.
| | - Anne Cust
- Sydney School of Public Health, Sydney Medical School, University of Sydney, Level 6, 119-143 Missenden Road, Camperdown, NSW, 2050, Australia.
| | - Richard Gallagher
- Cancer Control Research Program, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada.
| | - Tim K Lee
- Cancer Control Research Program, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada.
| | - Frank Meyskens
- Public Health and Epidemiology, University of California, Irvine, USA.
| | - Shaily Pandey
- Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY, 10029, USA.
| | - Nancy E Thomas
- University of North Carolina, 413 Mary Ellen Jones Bldg. CB#7287, Chapel Hill, NC, 275992, USA.
| | - Marit B Veierød
- Department of Biostatistics, Institute of Basic Medical Sciences, P.O. Box 1122 Blindern, 0317, Oslo, Norway.
| | - Sarah Ward
- Centre for Genetic Origins of Health and Disease (GOHaD), The University of Western Australia, M409, 35 Stirling Hwy, Crawley, WA, 6009, Australia.
| |
Collapse
|
12
|
MacGregor S, Brown KM, Stark M, Gartside M, Woods S, Bonazzi V, Aoude L, Dutton-Regester K, Tyagi S, Liu J, Duffy DL, Palmer J, Cust A, Schmid H, Symmons J, Holland E, Agha-Hamilton C, Holohan K, Youngkin D, Gillanders E, Jenkins MA, Kelly J, Whiteman DC, Kefford R, Giles G, Armstrong B, Aitken J, Hopper J, Montgomery G, Schmidt C, Trent JM, Martin NG, Mann GJ, Hayward NK. From GWAS to genome sequencing: complementary approaches to identify melanoma predisposition genes. Hered Cancer Clin Pract 2012. [PMCID: PMC3327126 DOI: 10.1186/1897-4287-10-s2-a46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
13
|
Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, MacGregor S, Hayward NK, Martin NG, Duffy DL, Mann GJ, Cust A, Hopper J, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet 2011; 20:5012-23. [PMID: 21926416 DOI: 10.1093/hmg/ddr415] [Citation(s) in RCA: 169] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
We performed a multistage genome-wide association study of melanoma. In a discovery cohort of 1804 melanoma cases and 1026 controls, we identified loci at chromosomes 15q13.1 (HERC2/OCA2 region) and 16q24.3 (MC1R) regions that reached genome-wide significance within this study and also found strong evidence for genetic effects on susceptibility to melanoma from markers on chromosome 9p21.3 in the p16/ARF region and on chromosome 1q21.3 (ARNT/LASS2/ANXA9 region). The most significant single-nucleotide polymorphisms (SNPs) in the 15q13.1 locus (rs1129038 and rs12913832) lie within a genomic region that has profound effects on eye and skin color; notably, 50% of variability in eye color is associated with variation in the SNP rs12913832. Because eye and skin colors vary across European populations, we further evaluated the associations of the significant SNPs after carefully adjusting for European substructure. We also evaluated the top 10 most significant SNPs by using data from three other genome-wide scans. Additional in silico data provided replication of the findings from the most significant region on chromosome 1q21.3 rs7412746 (P = 6 × 10(-10)). Together, these data identified several candidate genes for additional studies to identify causal variants predisposing to increased risk for developing melanoma.
Collapse
Affiliation(s)
- Christopher I Amos
- Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F, Panico S, Larrañaga N, Pera G, Tormo MJ, Sánchez MJ, Ramón Quirós J, Ardanaz E, Tjønneland A, Olsen A, Chang-Claude J, Linseisen J, Schulz M, Boeing H, Lundin E, Palli D, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Bingham S, Khaw KT, Bas Bueno-de-Mesquita H, Trichopoulou A, Trichopoulos D, Naska A, Tumino R, Riboli E, Kaaks R. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008; 15:485-97. [PMID: 18509001 PMCID: PMC2396334 DOI: 10.1677/erc-07-0064] [Citation(s) in RCA: 188] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Epidemiological data show that reproductive and hormonal factors are involved in the etiology of endometrial cancer, but there is little data on the association with endogenous sex hormone levels. We analyzed the association between prediagnostic serum concentrations of sex steroids and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition using a nested case-control design of 247 incident endometrial cancer cases and 481 controls, matched on center, menopausal status, age, variables relating to blood collection, and, for premenopausal women, phase of menstrual cycle. Using conditional regression analysis, endometrial cancer risk among postmenopausal women was positively associated with increasing levels of total testosterone, free testosterone, estrone, total estradiol, and free estradiol. The odds ratios (ORs) for the highest versus lowest tertile were 2.66 (95% confidence interval (CI) 1.50-4.72; P=0.002 for a continuous linear trend) for estrone, 2.07 (95% CI 1.20-3.60; P=0.001) for estradiol, and 1.66 (95% CI 0.98-2.82; P=0.001) for free estradiol. For total and free testosterone, ORs for the highest versus lowest tertile were 1.44 (95% CI 0.88-2.36; P=0.05) and 2.05 (95% CI 1.23-3.42; P=0.005) respectively. Androstenedione and dehydroepiandrosterone sulfate were not associated with risk. Sex hormone-binding globulin was significantly inversely associated with risk (OR for the highest versus lowest tertile was 0.57, 95% CI 0.34-0.95; P=0.004). In premenopausal women, serum sex hormone concentrations were not clearly associated with endometrial cancer risk, but numbers were too small to draw firm conclusions. In conclusion, relatively high blood concentrations of estrogens and free testosterone are associated with an increased endometrial cancer risk in postmenopausal women.
Collapse
Affiliation(s)
| | | | - Laure Dossus
- Division of Cancer EpidemiologyDeutsches KrebsforschungszentrumIm Neuenheimer Feld 280, 69120 HeidelbergGermany
| | - Sabina Rinaldi
- Nutrition and Hormones GroupInternational Agency for Research on CancerLyonFrance
| | - Anne Cust
- Nutrition and Hormones GroupInternational Agency for Research on CancerLyonFrance
- University of Sydney, Sydney, Australia and University of Lyon 1LyonFrance
| | - Annekatrin Lukanova
- Division of Cancer EpidemiologyDeutsches KrebsforschungszentrumIm Neuenheimer Feld 280, 69120 HeidelbergGermany
| | - Petra H Peeters
- Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtUtrechtThe Netherlands
| | - N Charlotte Onland-Moret
- Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtUtrechtThe Netherlands
| | - Petra H Lahmann
- Medical Research Council Human Nutrition ResearchElsie Widdowson LaboratoryFulbourn Road, CambridgeUK
| | | | - Salvatore Panico
- Department of Clinical and Experimental MedicineFederico II UniversityNaplesItaly
| | - Nerea Larrañaga
- Public Health Department of Gipuzkoa, Basque GovernmentSan SebastianSpain
| | - Guillem Pera
- Department of EpidemiologyCatalan Institute of Oncology (ICO)BarcelonaSpain
| | | | | | - J Ramón Quirós
- Public Health & Health Planning DirectorateAsturiasSpain
| | - Eva Ardanaz
- Instituto de Salud Pública de NavarraPamplonaSpain
| | - Anne Tjønneland
- Institute of Cancer Epidemiology, Danish Cancer SocietyCopenhagenDenmark
| | - Anja Olsen
- Institute of Cancer Epidemiology, Danish Cancer SocietyCopenhagenDenmark
| | - Jenny Chang-Claude
- Division of Cancer EpidemiologyDeutsches KrebsforschungszentrumIm Neuenheimer Feld 280, 69120 HeidelbergGermany
| | - Jakob Linseisen
- Division of Cancer EpidemiologyDeutsches KrebsforschungszentrumIm Neuenheimer Feld 280, 69120 HeidelbergGermany
| | - Mandy Schulz
- German Institute of Human NutritionPotsdam-Rehbücke, Germany
| | - Heiner Boeing
- German Institute of Human NutritionPotsdam-Rehbücke, Germany
| | - Eva Lundin
- Department of Nutritional ResearchUniversity of UmeåUmeåSweden
| | - Domenico Palli
- Molecular and Nutritional Epidemiology UnitCSPO-Scientific Institute of TuscanyFlorenceItaly
| | - Kim Overvad
- Department of Clinical EpidemiologyAalborg Hospital, Aarhus University HospitalAalborgDenmark
| | | | | | - Sheila Bingham
- MRC Dunn Human Nutrition UnitUniversity of CambridgeCambridgeUK
| | - Kay-Tee Khaw
- Clinical Gerontology UnitAddenbrooke's HospitalCambridgeUK
| | - H Bas Bueno-de-Mesquita
- National Institute of Public Health and the EnvironmentCenter for Nutrition and HealthBilthovenThe Netherlands
| | - Antonia Trichopoulou
- Department of Hygiene and EpidemiologySchool of Medicine, University of AthensAthensGreece
| | - Dimitiros Trichopoulos
- Department of Hygiene and EpidemiologySchool of Medicine, University of AthensAthensGreece
| | - Androniki Naska
- Department of Hygiene and EpidemiologySchool of Medicine, University of AthensAthensGreece
| | - Rosario Tumino
- Cancer Registry Azienda Ospedaliera ‘Civile M P Arezzo’RagusaItaly
| | - Elio Riboli
- Department of Epidemiology and Public Health, Faculty of Medicine, Cancer Epidemiology and PreventionImperial College LondonLondonUK
| | - Rudolf Kaaks
- Division of Cancer EpidemiologyDeutsches KrebsforschungszentrumIm Neuenheimer Feld 280, 69120 HeidelbergGermany
| |
Collapse
|
15
|
Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, Tjønneland A, Olsen A, Overvad K, Grønbaek H, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Boeing H, Pischon T, Trichopoulos D, Oikonomou E, Trichopoulou A, Panico S, Vineis P, Berrino F, Tumino R, Masala G, Peters PH, van Gils CH, Bueno-de-Mesquita HB, Ocké MC, Lund E, Mendez MA, Tormo MJ, Barricarte A, Martínez-García C, Dorronsoro M, Quirós JR, Hallmans G, Palmqvist R, Berglund G, Manjer J, Key T, Allen NE, Bingham S, Khaw KT, Cust A, Kaaks R. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121:368-76. [PMID: 17372899 DOI: 10.1002/ijc.22697] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Western style diets and lifestyles are associated with increasing rates of obesity, diabetes and insulin resistance. Higher circulating insulin levels may modulate cell proliferation and apoptosis either directly or indirectly by increasing the bioactivity of IGF-I and decreasing the bioactivity of some of its binding proteins. The objective of this study was to determine the association of increasing levels of serum C-peptide, a biomarker of pancreatic insulin secretion, and IGF binding proteins (IGFBP) -1 and -2 with colorectal cancer risk in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), a large cohort involving 10 Western European countries. A total of 1,078 colorectal cancer cases were matched (age, date of blood donation, fasting status, gender, study center) to an equal number of control subjects. Relative cancer risks were estimated using conditional logistic regression models. Serum C-peptide concentration was positively associated with an increased colorectal cancer risk for the highest versus the lowest quintile (OR=1.56, 95% CI=1.16-2.09, p(trend)<0.01), which was slightly attenuated after adjustment for BMI and physical activity (OR=1.37, 95% CI=1.00-1.88, p(trend)=0.10). When stratified by anatomical site, the cancer risk was stronger in the colon (OR=1.67, 95% CI=1.14-2.46, p(trend)<0.01) than in the rectum (OR=1.42, 95% CI=0.90-2.25, p(trend)=0.35). The cancer risk estimates were not heterogeneous by gender or fasting status. No clear colorectal cancer risk associations were observed for IGFBP-1 or -2. This large prospective study confirms that hyperinsulinemia, as determined by C-peptide levels, is associated with an increased colorectal cancer risk.
Collapse
Affiliation(s)
- Mazda Jenab
- Nutrition and Hormones Group, IARC-WHO, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, Linseisen J, Rohrmann S, Pischon T, Schulz M, Tjønneland A, Johnsen NF, Overvad K, Mendez M, Arguelles MV, Garcia CM, Larrañaga N, Chirlaque MD, Ardanaz E, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Dilis V, Trichopoulos D, Pala V, Palli D, Tumino R, Panico S, Vineis P, Bueno-de-Mesquita HB, Peeters PHM, Monninkhof E, Berglund G, Manjer J, Slimani N, Ferrari P, Kaaks R, Riboli E. Physical activity and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer 2007; 121:347-55. [PMID: 17357139 DOI: 10.1002/ijc.22676] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The etiologic role of physical activity in endometrial cancer risk remains unclear given the few epidemiologic studies that have been conducted. To investigate this relation more fully, an analysis was undertaken in the European prospective investigation into cancer and nutrition (EPIC). During an average 6.6 years of follow-up, 689 incident endometrial cancer cases were identified from an analytic cohort within EPIC of 253,023 women. Cox proportional hazards models were used to estimate the associations between type of activity (total, occupational, household, recreational) and endometrial cancer risk. For total activity, women in the highest compared with the lowest quartile of activity had a risk of 0.88 (95% confidence interval (95% CI=0.61-1.27). No clear associations between each type of activity and endometrial cancer risk were found for the total study population combined. Associations were more evident in the stratified results, with premenopausal women who were active versus inactive experiencing a risk of 0.66 (95% CI=0.38-1.14) overall. Among premenopausal women, for household and recreational activities the risk estimates in the highest as compared with the lowest quartiles were, respectively, 0.48 (95% CI=0.23-0.99) and 0.78 (95% CI=0.44-1.39). No effect modification by body mass index, hormone replacement therapy, oral contraceptive use or energy intake was found. This study provides no evidence of a protective effect of increased physical activity in endometrial cancer risk in all women but some support for a benefit among premenopausal women. The relative risk reductions are most apparent for household activities.
Collapse
Affiliation(s)
- Christine Friedenreich
- Division of Population Health and Information, Alberta Cancer Board, Calgary, Alberta, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, Linseisen J, Rohrmann S, Boeing H, Pischon T, Tjønneland A, Halkjaer J, Overvad K, Mendez M, Redondo ML, Garcia CM, Larrañaga N, Tormo MJ, Gurrea AB, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Vasilopoulou E, Trichopoulos D, Pala V, Palli D, Tumino R, Mattiello A, Vineis P, Bueno-de-Mesquita HB, Peeters PHM, Berglund G, Manjer J, Lundin E, Lukanova A, Slimani N, Jenab M, Kaaks R, Riboli E. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes Control 2007; 18:399-413. [PMID: 17297555 DOI: 10.1007/s10552-006-0113-8] [Citation(s) in RCA: 138] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Accepted: 12/21/2006] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To examine the association between anthropometry and endometrial cancer, particularly by menopausal status and exogenous hormone use subgroups. METHODS Among 223,008 women in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, there were 567 incident endometrial cancer cases during 6.4 years of follow-up. The analysis was performed with Cox proportional hazards modeling. RESULTS Weight, body mass index (BMI), waist and hip circumferences and waist-hip ratio (WHR) were strongly associated with increased risk of endometrial cancer. The relative risk (RR) for obese (BMI 30- < 40 kg/m(2)) compared to normal weight (BMI < 25) women was 1.78, 95% CI = 1.41-2.26, and for morbidly obese women (BMI > or = 40) was 3.02, 95% CI = 1.66-5.52. The RR for women with a waist circumference of > or =88 cm vs. <80 cm was 1.76, 95% CI = 1.42-2.19. Adult weight gain of > or =20 kg compared with stable weight (+/-3 kg) increased risk independent of body weight at age 20 (RR = 1.75, 95% CI = 1.11-2.77). These associations were generally stronger for postmenopausal than premenopausal women, and oral contraceptives never-users than ever-users, and much stronger among never-users of hormone replacement therapy compared to ever-users. CONCLUSION Obesity, abdominal adiposity, and adult weight gain were strongly associated with endometrial cancer risk. These associations were particularly evident among never-users of hormone replacement therapy.
Collapse
Affiliation(s)
- Christine Friedenreich
- Division of Population Health and Information, Alberta Cancer Board, T2N 4N2, Calgary, Alberta, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Steindorf K, Friedenreich C, Linseisen J, Rohrmann S, Rundle A, Veglia F, Vineis P, Johnsen NF, Tjønneland A, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Schulz M, Boeing H, Trichopoulou A, Kalapothaki V, Koliva M, Krogh V, Palli D, Tumino R, Panico S, Monninkhof E, Peeters PH, Boshuizen HC, Bueno-de-Mesquita HB, Chirlaque MD, Agudo A, Larrañaga N, Quirós JR, Martínez C, Barricarte A, Janzon L, Berglund G, Bingham S, Khaw KT, Key TJ, Norat T, Jenab M, Cust A, Riboli E. Physical activity and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition Cohort. Int J Cancer 2006; 119:2389-97. [PMID: 16894558 DOI: 10.1002/ijc.22125] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Research conducted predominantly in male populations on physical activity and lung cancer has yielded inconsistent results. We examined this relationship among 416,277 men and women from the European Prospective Investigation into Cancer and Nutrition (EPIC). Detailed information on recent recreational, household and occupational physical activity, smoking habits and diet was assessed at baseline between 1992 and 2000. Relative risks (RR) were estimated using Cox regression. During 6.3 years of follow-up we identified 607 men and 476 women with incident lung cancer. We did not observe an inverse association between recent occupational, recreational or household physical activity and lung cancer risk in either males or females. However, we found some reduction in lung cancer risk associated with sports in males (adjusted RR = 0.71; 95% confidence interval 0.50-0.98; highest tertile vs. inactive group), cycling (RR = 0.73; 0.54-0.99) in females and non-occupational vigorous physical activity. For occupational physical activity, lung cancer risk was increased for unemployed men (adjusted RR = 1.57; 1.20-2.05) and men with standing occupations (RR = 1.35; 1.02-1.79) compared with sitting professions. There was no evidence of heterogeneity of physical activity associations across countries, or across any of the considered cofactors. For some histologic subtypes suggestive sex-specific reductions, limited by subgroup sizes, were observed, especially with vigorous physical activity. In total, our study shows no consistent protective associations of physical activity with lung cancer risk. It can be assumed that the elevated risks found for occupational physical activity are not produced mechanistically by physical activity itself but rather reflect exposure to occupation-related lung cancer risk factors.
Collapse
Affiliation(s)
- Karen Steindorf
- Unit of Environmental Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
|
20
|
Mohan PV, Tarnow-Mordi W, Stenson B, Brocklehurst P, Haque K, Cavendish V, Cust A. Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants? Arch Dis Child Fetal Neonatal Ed 2004; 89:F5-8. [PMID: 14711844 PMCID: PMC1721634 DOI: 10.1136/fn.89.1.f5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Recent evidence suggests that inflammatory cytokines may play an important role in cerebral and pulmonary injury, especially in preterm infants. Immunomodulatory agents may help to limit such injury by reducing inflammation. Immunoglobulin has multiple anti-inflammatory properties and can modulate the inflammatory cytokine response. New evidence is required to test the hypotheses that prophylaxis or treatment with intravenous immunoglobulin may limit such inflammatory damage.
Collapse
Affiliation(s)
- P V Mohan
- Department of Paediatrics, Baylor College of Medicine, Houston, TX 77025, USA.
| | | | | | | | | | | | | |
Collapse
|
21
|
Tarnow-Mordi W, Cust A, Brocklehurst P, Mohan P, Isaacs D. Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants. Lancet 2002; 359:1522; author reply 1523-4. [PMID: 11988276 DOI: 10.1016/s0140-6736(02)08446-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|